Dongyang Pharmaceutical (06887)'s self-developed glycine insulin injection has been approved for sale in the US

Zhitongcaijing · 1d ago

Zhitong Finance App News, Dongyang Pharmaceutical (06887) announced that the group's self-developed glycine insulin injection has obtained approval from the US Food and Drug Administration for marketing. This product is scheduled to be shipped in the near future. After the product is successfully shipped, the Group expects to launch the official commercialization of the product in the US market in due course. This milestone will further expand the company's overseas revenue, enhance the company's global competitiveness in hypoglycemic drugs, and accelerate the implementation of the strategic layout of internationalization and industrialization.